PATENT CLAIM ANALYSIS

Application Number: 15769079
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "337000"]

Abstract:
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B 4  receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B 4  receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

Claim (Index 6):
The compound according to  claim 1  wherein X is \u2014NHSO 2 CF 3 ; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 91.0
- Lexical Diversity: 1.7069
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15767371', '15768097', '12210247', '13371834', '10481352']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.786565367832109
- 35 USC 102 Novelty (BERT): 0.580196791910594
- Combined Prediction Score: 0.7659285102399576
- Mean Citation Score: 385.288128
- Max Citation Score: 501.19183
- Similarity Product: 367.39134636796655

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test